FilingSEC EDGAR8-K
Foghorn Therapeutics Announces Discontinuation of FHD-909 Trial and 40% Workforce Reduction
· SEC accepted
StageClinical Discontinuation
Filing content
Following a review of FHD-909 clinical data, the company decided to end its collaboration with Eli Lilly and reduce its workforce by approximately 40% to focus on priority programs.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…